SQZ Biotechnologies マネジメント

マネジメント基準チェック /24

SQZ Biotechnologiesの CEO はHoward Bernsteinで、 Nov2022年に任命され、の在任期間は 2.08年です。は、会社の株式の0.2%を直接所有しており、その価値は$ 1.67K 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と4.1年です。

主要情報

Howard Bernstein

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2yrs
CEOの所有権	0.2%
経営陣の平均在職期間	2.9yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

Jun 26

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Jan 05

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

Nov 09

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Oct 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Aug 20

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

Aug 04

SQZ Biotechnologies names business chief as CFO

Jul 11

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

May 17

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

May 16

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

Mar 25

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 20

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

Feb 01

CEO報酬分析

SQZ Biotechnologies の収益と比較して、Howard Bernstein の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2023	n/a	n/a	-US$72m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$76m
Dec 31 2022	US$2m	US$400k	-US$79m
Sep 30 2022	n/a	n/a	-US$78m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$74m
Dec 31 2021	US$1m	US$391k	-US$69m
Sep 30 2021	n/a	n/a	-US$75m
Jun 30 2021	n/a	n/a	-US$64m
Mar 31 2021	n/a	n/a	-US$55m
Dec 31 2020	US$750k	US$357k	-US$51m

報酬と市場: Howardの総報酬がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Howardの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Howard Bernstein (67 yo)

2yrs

在職期間

US$1,624,513

報酬

Dr. Howard Bernstein, M.D., Ph D., had been Chief Scientific Officer of SQZ Biotechnologies Company since June 2015 until October 31, 2022. Dr. Bernstein is Director of SQZ Biotechnologies Company since Oc...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Howard Bernstein	Interim CEO & Director	2yrs	US$1.62m	0.20% $ 1.7k
Lawrence Knopf	General Counsel & Secretary	5.2yrs	US$944.03k	0.0066% $ 54.3
Marshelle Warren	Chief Medical Officer	2.4yrs	US$944.27k	0% $ 0
Robert Langer	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Richard Capasso	Chief Accounting Officer	3yrs	データなし	データなし
David First	Chief People Officer	4.5yrs	データなし	データなし
Ipsita Roymoulik	Senior Vice President of CMC & QUALITY	2.8yrs	データなし	データなし

2.9yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: SQZBの経営陣は経験豊富であると考えられます ( 2.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Howard Bernstein	Interim CEO & Director	2.1yrs	US$1.62m	0.20% $ 1.7k
Robert Langer	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
David Sachs	Member of Scientific Advisory Board	no data	データなし	データなし
Amy W. Schulman	Director	no data	US$104.40k	0.74% $ 6.1k
Patrick V. J. Vink	Independent Director	3.3yrs	US$96.62k	0% $ 0
Klavs Jensen	Independent Director	11.7yrs	US$89.40k	1.15% $ 9.5k
Bernard Coulie	Independent Chairman	3.3yrs	US$94.40k	0% $ 0
Marc Elia	Independent Director	6.5yrs	US$86.90k	0% $ 0
Darrell Irvine	Member of Scientific Advisory Board	no data	データなし	データなし
Pushkal Garg	Independent Director	6.3yrs	US$94.40k	0% $ 0
Marc Schegerin	Independent Director	4.1yrs	US$94.40k	0% $ 0
Arlene Sharpe	Member of Scientific Advisory Board	no data	データなし	データなし

4.1yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: SQZBの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

SQZ Biotechnologies マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

High number of new directors

SQZ Biotechnologies Announces Resignation of Micah Zajic as Chief Financial Officer, Effective December 31, 2022

SQZ Biotechnologies Company Announces Leadership Transition

SQZ Biotechnologies Company Appoints Micah Zajic as Principal Financial Officer

SQZ Biotechnologies Appoints Marshelle Smith Warren as Chief Medical Officer

Independent Director recently bought US$50k worth of stock

Recent updates

SQZ Biotechnologies Files Form 15

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies Company(OTCPK:SQZB) dropped from S&P TMI Index

New major risk - Market cap size

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

SQZ Biotechnologies Receives Written Notice from the NYSE Regarding Non-Compliance with Section 802.01B of the NYSE Listed Company Manual

First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.75 loss in 1Q 2022)

Price target increased by 44% to US$19.00

Full year 2022 earnings: EPS and revenues exceed analyst expectations

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress

High number of new directors

Price target decreased to US$15.40

SQZ Biotechnologies Announces Resignation of Micah Zajic as Chief Financial Officer, Effective December 31, 2022

Price target decreased to US$17.67

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$0.80 loss in 3Q 2021)

SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Sqz Biotechnologies Publishes Preclinical Research Demonstrating Sqz® Aac Platform’S Potential as an Effective Red Blood Cell-Derived Immunotherapy

SQZ Biotechnologies Company Presents Preclinical SQZ TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies

SQZ Biotechnologies Company Announces Leadership Transition

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ(R) APCs and Effective CD8 T Cell Activation

SQZ Biotechnologies Company Appoints Micah Zajic as Principal Financial Officer

SQZ Biotechnologies names business chief as CFO

SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Index

Price target decreased to US$25.17

SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs

SQZ Biotechnologies Appoints Marshelle Smith Warren as Chief Medical Officer

Independent Director recently bought US$50k worth of stock

Price target decreased to US$27.50

SQZ Biotechnologies Announces Integrated Point-Of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than A More Conventional Clean Room-Based Process

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

First quarter 2022 earnings: EPS and revenues miss analyst expectations

SQZ Biotechnologies Company Announces First Data Presentation on Non-Clinical Studies of Point-Of-Care Manufacturing System

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Price target decreased to US$30.60

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$31.00

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ

SQZ Biotechnologies Company Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

SQZ Biotechnologies Company Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint Hpv+ Solid Tumor Patient

SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

SQZ Biotechnologies Company Announces Acceptance by Roche Accelerator in China

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$7.03 loss in 3Q 2020)

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

Second quarter 2021 earnings released: US$0.68 loss per share (vs US$6.05 loss in 2Q 2020)

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Growth Index

SQZ Biotechnologies Company Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor

SQZ Biotechnologies Company Tolerizing Antigen Carrier Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

SQZ Biotechnologies Presents Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors

SQZ Biotechnologies Company to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

First quarter 2021 earnings released: US$0.59 loss per share (vs US$6.41 loss in 1Q 2020)

SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

マネジメント基準チェック /24